Blinding and Masking in Clinical Trials

In a clinical trial, blinding (the term used throughout most of the methodological literature) and masking (the term FDA and ICH guidance now prefer, to avoid confusion with visual impairment in trials involving ophthalmologic or otherwise vision-related conditions) refer to the same procedure: withholding knowledge of treatment assignment from one or more parties to a trial — participants, treating clinicians, outcomes assessors, and/or data analysts — after randomization has occurred. The two words are used interchangeably in practice; ICH E6’s own glossary entry is still titled “Blinding/Masking,” and ClinicalTrials.gov’s public data element is labeled Masking. This is a distinct concept from randomization and allocation concealment, which happen before and at the point of assignment — masking concerns who knows the assignment afterward, and addresses a different bias category (performance bias, from differential care or behavior, and detection/ascertainment bias, from differential outcome assessment) than randomization’s selection-bias mitigation.

Masking vs. blinding: which term to use

Both terms describe the identical procedure. “Blinding” remains dominant in academic and statistical literature and in widely used reporting guidelines such as CONSORT 2010. FDA and ICH guidance increasingly favor “masking” specifically because “blind” and “blinding” can be read as referring to visual impairment, which is a genuine source of confusion in trials that recruit visually impaired participants or that study ophthalmologic interventions. ClinicalTrials.gov’s protocol registration system uses “Masking” as the formal data element name. In practice, drafters of protocols, consent forms, and regulatory submissions should default to “masking” for precision and to match current regulatory house style, while recognizing that “blinding” will continue to appear throughout the existing literature and in older trials’ documentation.

Why trials mask treatment assignment

Masking exists to prevent expectation effects from contaminating a trial’s results. If participants know they are receiving an active treatment, their reported symptoms, adherence, or behavior can shift independent of any real pharmacological or procedural effect — this is performance bias. If the clinician delivering care or the assessor recording outcomes knows the assignment, their judgment in ambiguous cases can shift toward or away from a hypothesized effect — this is detection (ascertainment) bias. Masking as many of these roles as is ethically and practically feasible reduces both. A trial can still be a fully valid randomized controlled trial without any masking at all — masking is a separate design axis from randomization and the presence of a control arm, not a requirement for a study to count as an RCT.

Levels of masking

ClinicalTrials.gov’s Masking data element records two things: how many distinct roles are kept unaware of assignment, and which roles those are. The commonly used level labels are:

• None (open-label) — every party, including the participant, knows the assignment.
• Single — typically the participant alone is masked.
• Double — typically the participant and the investigator/care provider are both masked.
• Triple — adds the outcomes assessor to the masked roles.
• Quadruple — adds the data analyst as well, so that statistical analysis is also conducted without knowledge of assignment.

The specific roles that can realistically be masked in a given trial — participant, care provider/investigator, outcomes assessor, data analyst — depend heavily on the intervention type. A trial comparing two visually identical tablets can mask everyone; a trial comparing surgery to a non-surgical intervention often cannot mask the operating team, even if the outcomes assessor and data analyst still can be.

Mechanisms used to achieve masking

Common mechanisms include:

• Matched placebo — a comparator formulated to be indistinguishable from the active treatment in appearance, taste, smell, and administration route. See Placebo-Controlled Study Design.
• Sham procedures — for device, surgical, or procedural interventions where no pill-form comparator is possible, a simulated version of the procedure is performed on control-arm participants, matching sensory and experiential cues without delivering the active mechanism. See the dedicated guide on Sham Procedure Design in Device Clinical Trials for the ethical and design considerations specific to this mechanism.
• Independent unmasking protocols — a pre-specified procedure allowing a designated, otherwise-uninvolved party (often tied to a Data Safety Monitoring Board or a dedicated unmasking/emergency-unblinding pathway within the trial’s Interactive Response Technology system) to unmask a specific participant’s assignment in a medical emergency, without unmasking the rest of the trial. This preserves the overall trial’s masking integrity while allowing individual-participant safety decisions when unmasked information is clinically necessary.

When masking isn’t possible

Some comparisons cannot realistically be masked for every role — a trial comparing two distinct surgical techniques, a behavioral intervention versus usual care, or an intervention with a highly distinctive side-effect profile (e.g., a drug that visibly discolors urine) may only be able to mask the outcomes assessor and data analyst, or may be open-label throughout. An open-label design is not inherently invalid: it remains a legitimate randomized controlled trial provided randomization and a genuine control condition are both present, though it is more vulnerable to performance and detection bias and typically calls for stronger safeguards elsewhere — objective, hard outcome measures less susceptible to subjective judgment, and masking whichever roles remain feasible (most often the outcomes assessor and data analyst, sometimes called PROBE, “Prospective, Randomized, Open, Blinded Endpoint,” design).

Frequently asked questions

Is masking the same thing as allocation concealment?

No. Allocation concealment happens at the point of enrollment and prevents whoever is enrolling participants from knowing or predicting the upcoming assignment before it is made, which protects against selection bias. Masking happens after assignment and protects against performance and detection bias. A trial can have strong allocation concealment and no masking at all, or vice versa — they are frequently confused but are distinct methodological safeguards.

Does FDA require masking in every trial?

No. FDA and ICH guidance describe masking as a design choice to be applied to the extent feasible for the intervention being studied, not a universal requirement. Many legitimate, approvable trials are open-label, particularly where masking is not practically achievable (e.g., comparing two distinct surgical approaches) or where masking would itself introduce unacceptable risk or complexity.

What is a “double-masked” trial?

A double-masked (double-blind) trial is one in which both the participant and the investigator or care provider delivering treatment are unaware of the treatment assignment, most commonly achieved through a matched placebo or an equivalent comparator that cannot be distinguished from the active treatment.

Who can unmask a participant during a trial?

Trials with masking in place should have a pre-specified emergency unmasking procedure, typically involving a designated safety contact or the trial’s Interactive Response Technology system, allowing an individual participant’s assignment to be revealed to the minimum necessary personnel when clinically required — without unmasking the rest of the trial.